Lurasidone Improves Psychopathology and Cognition in Treatment-Resistant Schizophrenia.

J Clin Psychopharmacol · 2020 · PMC7188269 · PMID 32332459

Europe PMC DOI

hedged sentences

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

showed a trendP = 0.07so close (0.05 < p ≤ 0.1)

The PSP showed a trend of improvement at week 6 ( P = 0.07) and was significantly improved in both groups, beginning at week 12 of phase 2 ( F = 13.22, P = 0.0001, ES = 0.60).

also in 53,322 other papers

highly significantno p-value reported

33 Lurasidone produced highly significant improvement in non-TRS patient in 6-week studies at doses of 40 to 160 mg/d. 34 – 38 One clinical trial with non-TRS patients reported that improvement in psychopathology was greater with higher doses of lurasidone (160 mg/d) compared with lower doses. 36 As previously mentioned, the duration of tr

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.